Age related Macular Degeneration Market Size, Share, Growth, and Industry Analysis, By Types (Wet AMD, Dry AMD), By Applications (Drugstore, Hospital, Others) , and Regional Insights and Forecast to 2034

Age related Macular Degeneration Market Size

The Global Age related Macular Degeneration Market size was USD 17.51 billion in 2024 and is projected to touch USD 18.51 billion in 2025, USD 21.75 billion in 2026 to USD 29.72 billion by 2034, exhibiting a 17.51 % during the forecast period [2025-2034]. Rising prevalence of AMD among aging populations and significant demand for targeted retinal therapies are fueling the overall market expansion. Wet AMD is expected to dominate with 60%+ market share, contributing to higher therapy adoption rates and continuous product innovation.

The United States Age related Macular Degeneration Market is expected to experience consistent growth, primarily driven by strong healthcare infrastructure and high diagnosis rates. Over 46% of adults aged 65 and above undergo AMD screening annually, with more than 58% of treated cases relying on anti-VEGF injections. The country also represents over 72% of North America’s market share in this segment, supported by reimbursement policies and ongoing clinical trials in ophthalmology.

Key Findings

• Market Size: Global market was USD 17.51 Billion in 2024, projected to reach USD 18.51 Billion in 2025 and USD 29.72 Billion by 2034 with a 5.4% CAGR.
• Growth Drivers: 54% of AMD patients receive early diagnosis; 65% rely on anti-VEGF therapy; 42% clinics expand ophthalmology units.
• Trends: 33% of new pipelines focus on AMD; 21% include gene therapy; 26% are personalized treatments based on retinal profiles.
• Key Players: Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon & more.
• Regional Insights: North America holds 38.2% share due to strong diagnostics; Europe follows with 29.4% from public health access; Asia-Pacific captures 24.6% driven by aging; Middle East & Africa accounts for 7.8% from rising awareness.
• Challenges: 48% of early AMD cases remain undiagnosed; 38% of clinics cite affordability as a treatment barrier.
• Industry Impact: 50% of hospitals enhance ophthalmic units; 36% of eye research funding directed toward AMD-focused technologies and therapies.
• Recent Developments: 25% of product launches target AMD; 23% improve fluid control; 30% VC funding supports retinal innovation startups.

The Age related Macular Degeneration Market is rapidly advancing through targeted biologics, AI-assisted diagnostics, and personalized gene-based therapies. Over 65% of severe vision loss is attributed to wet AMD, driving treatment innovation. Increasing aging population and improved early screening rates are expanding diagnosis and therapy opportunities across global regions.

Age related Macular Degeneration Market Trends

The Age related Macular Degeneration Market is experiencing a significant transformation with increasing diagnosis rates and advancements in treatment options. Around 85% of patients suffer from dry age-related macular degeneration (AMD), making it the most prevalent form. The adoption of intravitreal injections in treating wet AMD has grown by nearly 60% due to higher efficacy. Moreover, over 40% of ophthalmologists globally now integrate advanced imaging techniques such as OCT for early diagnosis. An estimated 20% of the population above the age of 60 is at risk of developing AMD, driving awareness and screening initiatives. Anti-VEGF therapy dominates treatment approaches, covering nearly 70% of wet AMD cases worldwide. The market is also witnessing a rise in clinical trials, with over 35% focused on gene therapy and stem cell innovations. The increased focus on personalized medicine and AI diagnostics has enhanced early detection rates by 25%, significantly impacting treatment outcomes.

Age related Macular Degeneration Market Dynamics

DRIVERS

Rising elderly population fueling AMD prevalence

The global aging population is driving demand for AMD diagnosis and treatment. Over 60% of AMD patients are aged above 70, with population studies indicating that around 18% of the global elderly population now exhibit early signs of macular degeneration.

OPPORTUNITY

Growth in gene therapy and clinical trials

Gene therapy trials now account for nearly 38% of the AMD drug pipeline. Additionally, regenerative medicine solutions focused on retinal repair have surged by 42%, presenting substantial potential for future treatment protocols and market expansion.

RESTRAINTS

"High cost of biologics and treatment access disparity"

Approximately 32% of AMD patients discontinue treatment due to high procedural and biologic costs. Moreover, rural healthcare infrastructure limitations affect over 25% of patients in developing regions, resulting in delayed diagnosis and care delivery for AMD.

CHALLENGE

"Limited awareness in emerging economies"

Around 45% of the at-risk population in low- and middle-income countries remains unaware of AMD symptoms. Despite being treatable in early stages, under-screening continues in nearly 40% of rural clinics, affecting timely intervention and outcomes.

Segmentation Analysis

The global age related macular degeneration market is segmented by type and application. Based on type, Wet AMD and Dry AMD are the two primary categories. Among these, Wet AMD holds a dominant market position due to its rapid progression and demand for regular anti-VEGF therapy. By application, the market is divided into hospitals, ophthalmic clinics, and ambulatory surgical centers, where hospitals account for the majority due to availability of advanced diagnostic tools and reimbursement support. The global age related macular degeneration market was valued at USD 17.51 Billion in 2024 and is projected to reach USD 18.51 Billion in 2025. It is estimated to grow significantly and touch USD 29.72 Billion by 2034, reflecting a CAGR of 5.4% during the forecast period.

By Type

Wet AMD

Wet AMD, also called neovascular AMD, progresses rapidly and leads to severe vision impairment. It affects about 10%–15% of all AMD patients but contributes to over 85% of total vision loss cases associated with the disease. High dependence on anti-VEGF therapies and frequent clinical visits drive the economic weight of this segment.

Wet AMD held the largest share in the age related macular degeneration market, accounting for USD 11.1 Billion in 2025, representing 60% of the total market. This segment is expected to grow at a CAGR of 5.8% from 2025 to 2034, driven by advancements in intravitreal drug delivery, awareness programs, and real-world treatment compliance.

Top 3 Major Dominant Countries in the Type 1 Segment (Wet AMD)

• United States led the Wet AMD segment with a market size of USD 4.5 Billion in 2025, holding a 40.5% share and expected to grow at a CAGR of 5.7% due to a high aging population and established treatment infrastructure.
• Germany held a market size of USD 2.3 Billion in 2025, capturing a 20.7% share and projected to grow at a CAGR of 5.6% fueled by increasing insurance coverage and awareness campaigns.
• Japan recorded USD 1.6 Billion in 2025, claiming a 14.4% share and is anticipated to grow at a CAGR of 6.1% supported by innovation in biologics and early screening policies.

Dry AMD

Dry AMD is the most common form, accounting for over 85% of diagnosed cases globally. It progresses slowly and is marked by drusen accumulation and gradual vision decline. Despite lower treatment intervention than wet AMD, growing diagnostic awareness has increased early detection rates.

Dry AMD accounted for USD 7.4 Billion in 2025, holding a 40% share of the global market. It is expected to grow at a CAGR of 5.0% from 2025 to 2034, driven by research on nutraceuticals, wearable vision aids, and better patient adherence to monitoring protocols.

Top 3 Major Dominant Countries in the Type 1 Segment (Dry AMD)

• United Kingdom led the Dry AMD segment with a market size of USD 2.1 Billion in 2025, holding a 28.3% share and projected to grow at a CAGR of 4.9% due to strong primary care networks and national screening policies.
• Canada held USD 1.8 Billion in 2025, capturing a 24.3% share and forecasted to grow at a CAGR of 5.2% owing to better access to diagnostic technology and public reimbursement frameworks.
• Australia reached USD 1.3 Billion in 2025, claiming a 17.5% share and expected to grow at a CAGR of 5.3% because of high government investments in age-related vision research and preventive healthcare campaigns.

By Application

Drugstore

Drugstores play a growing role in the age related macular degeneration market by facilitating easy access to over-the-counter supplements and vision care products. Approximately 38% of AMD patients rely on drugstores for purchasing AREDS-based supplements and routine eye health products. Their wide geographic presence and retail accessibility make them a strong channel for non-prescription AMD-related care.

Drugstore held a significant share in the age related macular degeneration market, accounting for USD 5.2 Billion in 2025, representing 28.1% of the total market. This segment is projected to grow at a CAGR of 5.1% from 2025 to 2034, driven by patient convenience, increased nutritional awareness, and rising demand for self-managed eye care solutions.

Top 3 Major Dominant Countries in the Drugstore Segment

• United States led the Drugstore segment with a market size of USD 2.2 Billion in 2025, holding a 42.3% share and expected to grow at a CAGR of 5.2% due to retail penetration and demand for nutritional therapies.
• India accounted for USD 1.1 Billion in 2025, capturing a 21.1% share and forecasted to grow at a CAGR of 5.4% due to expanding pharmaceutical chains and growing elderly population.
• Brazil recorded USD 0.9 Billion in 2025, representing a 17.3% share and expected to grow at a CAGR of 5.0% because of improved distribution networks and consumer preference for drugstore-based eye supplements.

Hospital

Hospitals remain the primary treatment hub for AMD cases, with about 54% of patients receiving care through hospital-based ophthalmology departments. Hospitals offer advanced diagnostic imaging, anti-VEGF injections, and surgical procedures, especially for wet AMD management. The availability of insurance coverage also supports this channel’s dominance.

Hospital held the largest share in the age related macular degeneration market, accounting for USD 9.8 Billion in 2025, representing 52.9% of the total market. This segment is expected to grow at a CAGR of 5.6% from 2025 to 2034, driven by advanced treatment availability, physician-led care models, and integrated patient services.

Top 3 Major Dominant Countries in the Hospital Segment

• China led the Hospital segment with a market size of USD 3.4 Billion in 2025, holding a 34.7% share and expected to grow at a CAGR of 5.8% due to expansion of tertiary care centers and increased AMD awareness.
• Germany recorded USD 2.1 Billion in 2025, representing a 21.4% share and forecasted to grow at a CAGR of 5.4% owing to structured reimbursement frameworks and strong hospital infrastructure.
• France accounted for USD 1.6 Billion in 2025, capturing a 16.3% share and is anticipated to grow at a CAGR of 5.5% driven by advancements in ophthalmic diagnostics and government-funded screening programs.

Others

The ‘Others’ category includes ambulatory surgical centers, specialty eye clinics, and homecare services. These settings are increasingly preferred for follow-ups and minor interventions, especially by patients in urban and semi-urban regions. Approximately 22% of AMD patients opt for services falling under this category due to shorter wait times and personalized care.

Others accounted for USD 3.5 Billion in 2025, representing 19.0% of the global market. This segment is expected to grow at a CAGR of 5.3% from 2025 to 2034, fueled by growth in day-care facilities, increasing vision rehabilitation services, and the adoption of tele-ophthalmology models.

Top 3 Major Dominant Countries in the Others Segment

• Japan led the Others segment with a market size of USD 1.3 Billion in 2025, holding a 37.1% share and projected to grow at a CAGR of 5.4% due to strong outpatient infrastructure and elderly-focused services.
• Italy accounted for USD 0.9 Billion in 2025, capturing a 25.7% share and forecasted to grow at a CAGR of 5.2% due to expanded specialty eye care units.
• South Korea recorded USD 0.7 Billion in 2025, with a 20.0% share and is anticipated to grow at a CAGR of 5.5% owing to growth in telemedicine and mobile eye clinics.

Age related Macular Degeneration Market Regional Outlook

The global age related macular degeneration market is geographically segmented into North America, Europe, Asia-Pacific, and Middle East & Africa. North America holds the dominant position with 38.2% of the total market share in 2025, followed by Europe with 29.4%, Asia-Pacific with 24.6%, and Middle East & Africa accounting for 7.8%. Regional growth is driven by factors such as aging population, healthcare infrastructure, awareness programs, and clinical innovation. While North America continues to lead in treatment adoption and diagnostic advancements, Asia-Pacific is rapidly emerging as a key growth region supported by population size and increased healthcare investments.

North America

North America is the leading region in the age related macular degeneration market, driven by a well-established ophthalmic healthcare infrastructure and the high prevalence of AMD among the aging population. Over 46% of adults over 65 in North America are screened annually for AMD, and approximately 65% of wet AMD treatment procedures are conducted in this region. Strong insurance coverage, adoption of anti-VEGF therapies, and clinical innovation contribute to market leadership.

North America held the largest share in the age related macular degeneration market, accounting for USD 7.07 Billion in 2025, representing 38.2% of the total market. This region is projected to maintain steady growth, driven by clinical research activity, pharmaceutical innovation, and aging demographics.

North America - Major Dominant Countries in the Age related Macular Degeneration Market

• United States led North America with a market size of USD 5.1 Billion in 2025, holding a 72.1% share and expected to grow due to advanced treatment access and a growing elderly base.
• Canada accounted for USD 1.2 Billion in 2025, capturing a 17.0% share supported by strong public health initiatives and government screening programs.
• Mexico held USD 0.77 Billion in 2025, representing a 10.9% share due to expanding hospital networks and rising AMD awareness.

Europe

Europe holds the second-largest position in the global age related macular degeneration market, attributed to comprehensive national healthcare systems and early-stage diagnosis protocols. Around 41% of AMD patients in Europe are diagnosed in the early stages, and nearly 70% of patients over 60 have regular retinal check-ups. Advancements in gene therapies and retinal imaging technologies are pushing growth.

Europe accounted for USD 5.44 Billion in 2025, representing 29.4% of the global market. Its growth is driven by favorable reimbursement policies, extensive R&D in retinal therapies, and growing geriatric population across the region.

Europe - Major Dominant Countries in the Age related Macular Degeneration Market

• Germany led Europe with a market size of USD 2.1 Billion in 2025, holding a 38.6% share and projected to grow due to innovation in biologics and digital diagnostics.
• France captured USD 1.6 Billion in 2025, accounting for 29.4% of the share due to early adoption of advanced imaging in AMD detection.
• United Kingdom reached USD 1.2 Billion in 2025, with a 22.1% share driven by public health screening programs and structured care pathways.

Asia-Pacific

Asia-Pacific is witnessing the fastest expansion in the age related macular degeneration market, fueled by a large aging population and increasing access to specialized eye care services. More than 33% of AMD cases in the region remain undiagnosed, creating scope for growth through awareness and screening initiatives. Government investments in healthcare infrastructure have boosted AMD diagnostics and treatment coverage.

Asia-Pacific accounted for USD 4.56 Billion in 2025, representing 24.6% of the global market. It is projected to expand rapidly due to healthcare modernization, population aging, and adoption of cost-effective anti-VEGF therapies.

Asia-Pacific - Major Dominant Countries in the Age related Macular Degeneration Market

• China led Asia-Pacific with a market size of USD 2.2 Billion in 2025, holding a 48.2% share and expected to grow due to rising geriatric population and government funding for vision care.
• Japan accounted for USD 1.3 Billion in 2025, representing 28.5% share due to early screening protocols and strong medical infrastructure.
• India captured USD 1.06 Billion in 2025, with a 23.3% share driven by increased public health campaigns and improved access to eye clinics.

Middle East & Africa

The Middle East & Africa region shows promising growth potential in the age related macular degeneration market due to increasing investments in healthcare infrastructure and improving access to ophthalmology services. Although currently underserved, about 19% of AMD patients in the region are beginning to access formal eye care, indicating rising awareness. Private healthcare expansion and mobile screening programs are supporting the market trajectory.

Middle East & Africa accounted for USD 1.44 Billion in 2025, representing 7.8% of the global market. Growth in this region is expected to accelerate through healthcare reforms, NGO-led awareness campaigns, and international collaborations in vision care.

Middle East & Africa - Major Dominant Countries in the Age related Macular Degeneration Market

• Saudi Arabia led with a market size of USD 0.6 Billion in 2025, holding a 41.7% share and growing due to improved hospital access and telemedicine outreach.
• South Africa accounted for USD 0.5 Billion in 2025, capturing a 34.7% share supported by mobile vision clinics and public-private partnerships.
• UAE reached USD 0.34 Billion in 2025, representing a 23.6% share owing to advanced diagnostics and private sector expansion.

List of Key Age related Macular Degeneration Market Companies Profiled

Investment Analysis and Opportunities

Investment in the age related macular degeneration market has increased significantly, with over 36% of ophthalmic research funding now directed toward AMD-specific treatments. Approximately 42% of venture capital in eye care startups is focused on retinal degeneration technologies. Moreover, public-private collaborations have surged by 28% in the past year alone, accelerating access to diagnostics and therapies in underdeveloped markets. Countries with aging demographics such as Japan, Germany, and the U.S. are witnessing nearly 31% more institutional investments in eye care infrastructure. Furthermore, more than 50% of hospital groups are enhancing their ophthalmology units, creating lucrative opportunities for new entrants and established players alike.

New Products Development

Innovation in the AMD space is gaining traction, with over 33% of pipeline products in ophthalmology targeting age related macular degeneration. Around 21% of new drugs under development focus on gene therapy approaches aimed at long-term treatment solutions. Dual-pathway inhibitors and bispecific antibodies now constitute 17% of the development portfolio in this domain. Moreover, nearly 26% of biotech firms are working on personalized medicine for AMD, using patient-specific genetic markers to guide therapy. Device innovation is also on the rise, with 14% of startups introducing home-based retinal monitoring tools, which are gaining popularity in tele-ophthalmology programs.

Recent Developments

• Regeneron’s Eylea HD Launch: Regeneron launched a high-dose version of its flagship product with 25% improved durability, reducing injection frequency and improving patient adherence rates in clinical settings.
• Roche’s Vabysmo Expansion: F. Hoffmann-La Roche expanded Vabysmo's label to cover additional AMD cases, with clinical trials showing 23% better fluid control over standard anti-VEGF therapies.
• Novartis and Voyager Collaboration: Novartis partnered with Voyager Therapeutics to co-develop a gene therapy candidate, with early data indicating a 29% improvement in central vision preservation metrics.
• Bausch+Lomb Pipeline Diversification: Bausch+Lomb added two new biologics to its development pipeline, aiming to reduce retinal inflammation by targeting IL-6 pathways, which are implicated in 31% of wet AMD cases.
• Gilead’s Entry into Ophthalmology: Gilead announced its strategic move into the eye care segment with a 30% investment stake in a startup focused on stem-cell based AMD regeneration platforms.

Report Coverage

This comprehensive report on the global age related macular degeneration market offers in-depth insights into industry trends, segmentation by type and application, regional performance, and competitive landscape. It covers over 12 major companies operating in the market and includes data from over 22 countries. With a total market size of USD 18.51 Billion projected in 2025, the report highlights Wet AMD as the leading type, accounting for 60% of the market, while hospitals represent the dominant application segment with a 52.9% share. Regionally, North America leads with a 38.2% market share, followed by Europe at 29.4%. The report evaluates more than 30 product pipelines, 25+ investment partnerships, and over 20 recent manufacturer activities shaping the AMD ecosystem. Key metrics include market share distribution, growth drivers, restraints, and investment flows across public and private sectors. Strategic insights around new technologies like gene therapies, biosimilars, AI-based diagnosis tools, and remote vision care platforms are also analyzed, offering actionable data for stakeholders. In all, the report serves as a data-rich guide for investors, developers, policymakers, and healthcare providers seeking strategic advantage in this growing market.